-

The Phadia 2500+ Instrument Family Now Available in the U.S. for Autoimmune Testing

New offering from Thermo Fisher Scientific expands instrument capabilities beyond allergy diagnostics

PORTAGE, Mich.--(BUSINESS WIRE)--The new Phadia 2500+ series of instruments is now available for autoimmune testing in the U.S. The family of high-capacity, intuitive lab instruments supplied by Thermo Fisher Scientific, the world leader in serving science, offers reliable and unparalleled high throughput for both allergy diagnostics and autoimmune testing.

This expanded capability of the Phadia 2500+ series of instruments allows for instrument consolidation and enables additional automation for EliA autoimmune diagnostics, aiding in the diagnosis of autoimmune diseases including Connective Tissue Disease (CTD), Antiphospholipid Syndrome (APS), Celiac Disease, Rheumatoid Arthritis, Autoimmune Liver Disease and Autoimmune Thyroid Disease.

“Increasingly, laboratorians are being asked to further streamline their workflows and become more efficient,” said Michele Zwickl, vice president, commercial operations, U.S., ImmunoDiagnostics, Thermo Fisher. “With the launch of the Phadia 2500+ series, we now offer scalable, high-capacity allergy and autoimmune diagnostics instrumentation that can help large labs be more productive with existing resources.”

The Phadia 2500+ series of instruments is capable of serving laboratories with demands exceeding 10,000 test results every week and maximizes productivity by providing options to run EliA and ImmunoCAP testing in parallel on a single instrument. Its high throughput automation allows laboratories to process up to 480 ImmunoCAP results per hour and up to 300 EliA autoimmunity results per hour.

The series of instruments includes the Phadia 2500 (ImmunoCAP analyzer), Phadia 2500EE (EliA analyzer) and Phadia 2500E (ImmunoCAP and EliA analyzer). For more information on Phadia 2500+ series of instruments, please visit: https://www.thermofisher.com/phadia/us/en/our-solutions/phadia-laboratory-systems/phadia-2500.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media Contact Information:
Angela Christoforos
508-801-2391
achristoforos@greenough.biz

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media Contact Information:
Angela Christoforos
508-801-2391
achristoforos@greenough.biz

More News From Thermo Fisher

Thermo Fisher Scientific Opens U.S. Flagship Bioprocess Design Center to Accelerate the Delivery of Life-changing Therapies

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the opening of its flagship U.S. Bioprocess Design Center (BDC) at the company’s Plainville, Mass., site, expanding the facility to support customers in developing and scaling biologics. The new center brings together advanced bioproduction capabilities and hands-on collaboration to help customers accelerate process development and bring transformative therapies to patients faste...

Thermo Fisher Scientific to Host Investor Day

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, will hold its 2026 Investor Day on Wednesday, May 20, 2026, starting at 9:00 a.m. ET in New York City. The format will feature presentations by members of Thermo Fisher Scientific’s senior management team and conclude with a Q&A session. The live webcast of the presentation can be accessed via the Investors section of our website, https://ir.thermofisher.com. A replay of the webc...

Thermo Fisher Scientific Signs Agreement to Sell its Microbiology Business to Astorg

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has signed a definitive agreement to sell its microbiology business to Astorg, a leading pan-European private equity firm, for consideration of approximately $1.075 billion, consisting of cash and a $50 million seller note. The microbiology business provides antimicrobial susceptibility testing and culture media solutions for clinical, pharmaceutical and food...
Back to Newsroom